DexCom, Inc. Q2 2025 Earnings Recap

DexCom achieved a robust 15% organic revenue growth in Q2 2025, driven by strong demand in the U.S. and significant progress in expanding insurance coverage for type 2 diabetes patients.

Key Takeaways

• Launched type 2 non-insulin reimbursement, establishing coverage for nearly 6 million patients through the three largest PBMs in the U.S.
• Strong market share growth driven by heightened sales force effectiveness and increased access to healthcare providers.
• Over 400,000 downloads of the Stelo app reflect growing consumer interest in glucose monitoring and health wearables.
• Anticipating a successful second-half launch of the 15-day G7 System, with FDA clearance and reimbursement discussions on track.
• Introduced innovative AI features across products to enhance user experience and simplify diabetes management.